Amgen CEO named PhRMA board chairman-elect
WASHINGTON — The Pharmaceutical Research and Manufacturers of America has new officers on its board of directors. The organization has named Amgen chairman and CEO Robert Bradway to the chairman-elect position, effective immediately, and named two more industry executives to the board.
In addition to Bradway, Sanofi CEO Olivier Brandicourt will become chairman-elect and Astellas Americas president James Robinson will become treasurer, effective Feb. 7, 2018. Bradway, who was formerly board treasurer, succeeds Johnson & Johnson EVP and worldwide chairman pharmaceuticals Joaquin Duato as chairman-elect.
“I am pleased to welcome Bob to the board as our chairman-elect,” PhRMA president and CEO Stephen Ubl said. “Our companies are developing therapies unimaginable just a decade ago, and these advances will help many patients with serious and debilitating diseases. Together, we will ensure this innovation continues by advancing a comprehensive set of market-based reforms that improve access and affordability for patients.”
Bradway has been with Amgen since 2006, serving as CEO since 2012 and chairman since 2013. He also is the chairman of the CEO Roundtable on Cancer and is a member of Boeing’s board of directors. Brandicourt has been CEO of Sanofi since April 2015, joining the company from his post at Bayer Healthcare as a member of the executive leadership team. Robinson has led Astellas Americas since April 2016, having previously led its pharmaceuticals commercial in the organization in the United States. He joined the company in 2005 as VP health systems. Previously, he work with Schering-Plough, which was acquired by Merck in 2009.
“Now, more than ever, PhRMA member companies are bringing forth an unprecedented series of medical innovations to support human health,” Bradway said. Our innovations promise to not only improve and extend the lives of millions of patients, but also to positively bend the cost curve by decreasing the financial burden of serious diseases on society. I look forward to working together with stakeholders across the health care continuum to ensure a fertile environment for innovation and to encourage creative policy positions so that patients have access to the medicines they need.”